Loading clinical trials...
Loading clinical trials...
A Single-Center, Randomized, Open-Label, Two-Period, Two-Sequence, Single-Dose, Crossover Bioequivalence Study of Methylconalamin Injection and Methylconalamin for Injection in Healthy Subjects Under Fasting Conditions
Conditions
Interventions
Methylconalamin Injection(WP205)
Methylconalamin for Injection
Locations
1
China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Start Date
October 29, 2025
Primary Completion Date
November 6, 2025
Completion Date
November 25, 2028
Last Updated
December 15, 2025
Lead Sponsor
Wanbangde Pharmaceutical Group Co., LTD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions